TONG REN TANG TECHNOLOGIES CO. LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.76 HKD | +0.85% |
|
-5.74% | -27.33% |
| Sales 2023 | 6.77B 936M 7.33B | Sales 2024 * | 7.5B 1.04B 8.11B | Capitalization | 5.59B 772M 6.04B |
|---|---|---|---|---|---|
| Net income 2023 | 590M 81.49M 638M | Net income 2024 * | 631M 87.15M 682M | EV / Sales 2023 | 0.73 x |
| Net cash position 2023 | 2.66B 368M 2.88B | Net cash position 2024 * | 499M 68.97M 540M | EV / Sales 2024 * | 0.68 x |
| P/E ratio 2023 |
12.9
x | P/E ratio 2024 * |
8.81
x | Employees | 4,030 |
| Yield 2023 |
3.02% | Yield 2024 * |
3.9% | Free-Float | 45.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.85% | ||
| 1 week | -5.74% | ||
| Current month | -2.26% | ||
| 1 month | -6.67% | ||
| 3 months | -19.87% | ||
| 6 months | -16.64% | ||
| Current year | -27.33% |
1 week
4.67
5.04
1 month
4.675.26
Current year
4.676.66
1 year
4.678.97
3 years
3.809.28
5 years
3.8011.06
10 years
3.8016.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Fu Chen
CEO | Chief Executive Officer | 55 | 23-06-14 |
Guan Zhao Han
LAW | General Counsel | 45 | - |
Shu Wu Zhao
PRN | Corporate Officer/Principal | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leung Huel Ting
BRD | Director/Board Member | 70 | 00-10-10 |
Ching Har Chan
BRD | Director/Board Member | 67 | 18-06-11 |
Yuan Jing Zhan
BRD | Director/Board Member | 80 | 18-06-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.38% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 4.76 | +0.85% | 818 000 |
| 24-04-18 | 4.72 | -4.65% | 2,721,000 |
| 24-04-17 | 4.95 | +2.27% | 872,000 |
| 24-04-16 | 4.84 | -2.42% | 1,400,317 |
| 24-04-15 | 4.96 | -1.78% | 674,000 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 02:51 am EDT
More quotes
Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine products and health care products and the provision of traditional Chinese medicine diagnosis and treatment services. The Company is also engaged in the production, processing and acquisition of Chinese herbal medicines, drug sales, medical services and advertising. The Company mainly distributes its products in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.363
CNY
Average target price
6.058
CNY
Spread / Average Target
+38.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.33% | 772M | |
| +40.29% | 6.16B | |
| -15.73% | 4.49B | |
| -9.40% | 3.17B | |
| -1.60% | 3.01B | |
| -1.23% | 2.57B | |
| +34.89% | 1.8B | |
| -11.37% | 1.62B | |
| -5.02% | 1.56B | |
| -13.21% | 1.53B |
- Stock Market
- Equities
- 1666 Stock
